Drugs in Psychiatric Disorders Practice Questions

Q: A patient with severe anxiety requires long-term management. Which class of antidepressants, known for its efficacy in treating anxiety disorders, should be considered?

Selective serotonin reuptake inhibitors (SSRIs). ***Selective serotonin reuptake inhibitors (SSRIs)*** - SSRIs are considered **first-line agents** for the long-term management of most anxiety disorders due to their efficacy and generally favorable side-effect profile. - They work by increasing the concentration of **serotonin** in the synaptic cleft, helping to regulate mood and anxiety. - Evidence supports their use in generalized anxiety disorder, panic disorder, social anxiety disorder, and other anxiety conditions. *Tricyclic antidepressants* - While effective for some anxiety disorders, **TCAs** have a less favorable side-effect profile, including anticholinergic effects, sedation, and cardiac toxicity. - They are generally reserved for cases where SSRIs are ineffective or contraindicated. *Monoamine oxidase inhibitors* - **MAOIs** are highly effective but carry a significant risk of **hypertensive crisis** when consumed with tyramine-rich foods or certain medications. - Their strict dietary restrictions and drug interactions limit their use to **refractory cases** of anxiety. *Atypical antipsychotics* - **Atypical antipsychotics** are primarily used for psychotic disorders and severe mood disorders, sometimes as an augmentation strategy for anxiety. - They are not considered a first-line or long-term monotherapy for general anxiety due to potential side effects like metabolic syndrome and extrapyramidal symptoms.

Q: Which class of drugs is commonly used to treat anxiety by enhancing the effects of GABA?

Benzodiazepines. ***Benzodiazepines*** - **Benzodiazepines** act as positive **allosteric modulators** of the **GABA-A receptor**, increasing the frequency of **chloride channel opening**. - This enhanced **GABAergic transmission** leads to a **hyperpolarization** of neurons, resulting in reduced neuronal excitability, which exerts **anxiolytic**, sedative, and muscle relaxant effects. *Selective serotonin reuptake inhibitors* - **SSRIs** primarily increase the concentration of **serotonin** in the **synaptic cleft** by inhibiting its reuptake, rather than directly acting on GABA. - While effective for anxiety, their mechanism of action is distinct from GABA potentiation, and their therapeutic effects typically have a **delayed onset**. *Tricyclic antidepressants* - **TCAs** primarily inhibit the **reuptake of norepinephrine** and **serotonin**, and also block various receptors like **histaminic**, **cholinergic**, and **adrenergic receptors**. - They do not directly enhance **GABAergic activity**, and their use can be limited by a wide range of side effects due to their broad receptor blockade. *Monoamine oxidase inhibitors* - **MAOIs** prevent the enzymatic degradation of **norepinephrine**, **serotonin**, and **dopamine** by inhibiting the enzyme **monoamine oxidase**, thereby increasing their synaptic concentrations. - Their mechanism is focused on **monoamine neurotransmitters**, and they do not directly modulate **GABAergic transmission**.

Q: A patient being treated with an antipsychotic drug develops tardive dyskinesia. Which class of antipsychotic drugs is most commonly associated with this condition?

Typical antipsychotics. ***Typical antipsychotics*** - **First-generation antipsychotics**, also known as typical antipsychotics, are commonly associated with **tardive dyskinesia** due to their strong **D2 dopamine receptor blockade**. - Prolonged use leads to postsynaptic dopamine receptor hypersensitivity, resulting in involuntary movements. *Atypical antipsychotics* - **Second-generation antipsychotics** (atypical) have a **lower risk** of tardive dyskinesia due to their weaker D2 blockade and strong 5-HT2A serotonin receptor antagonism. - While the risk is present, it is significantly less compared to typical antipsychotics. *Dopamine partial agonists* - Drugs like **aripiprazole** (a dopamine partial agonist) have an even **lower risk of dyskinesia** because they modulate dopamine activity rather than completely blocking it. - They act as functional antagonists in areas with high dopamine and functional agonists in areas with low dopamine. *Anticholinergic drugs* - **Anticholinergic drugs** are sometimes used to treat **acute extrapyramidal symptoms** (like parkinsonism) caused by antipsychotics, but they do not cause or prevent tardive dyskinesia. - In some cases, discontinuing anticholinergics can unmask or worsen tardive dyskinesia.

Q: A 30-year-old man presents with symptoms of depression. He is prescribed a selective serotonin reuptake inhibitor (SSRI). Which of the following drugs is he most likely taking?

Fluoxetine. ***Fluoxetine*** - **Fluoxetine** is a prototypical **selective serotonin reuptake inhibitor (SSRI)**, commonly prescribed for depression. - SSRIs function by **blocking the reuptake of serotonin** in the presynaptic neuron, increasing its concentration in the synaptic cleft. *Amitriptyline* - **Amitriptyline** is a **tricyclic antidepressant (TCA)**, not an SSRI. - TCAs have a broader spectrum of action, blocking the reuptake of both **serotonin and norepinephrine**, and also affecting other receptors (e.g., muscarinic acetylcholine, histamine H1), leading to more side effects. *Venlafaxine* - **Venlafaxine** is a **serotonin-norepinephrine reuptake inhibitor (SNRI)**, not an SSRI. - SNRIs block the reuptake of both **serotonin and norepinephrine**, providing a dual mechanism of action that can be effective for some forms of depression or anxiety. *Mirtazapine* - **Mirtazapine** is an **atypical antidepressant** that primarily acts as an **alpha-2 adrenergic receptor antagonist**, which enhances noradrenergic and serotonergic transmission. - It also blocks 5-HT2 and 5-HT3 serotonin receptors and H1 histamine receptors, which contributes to its unique side effect profile (e.g., sedation, increased appetite).

Q: What is the most common electrolyte imbalance associated with lithium treatment?

Hypercalcemia (high calcium levels). ***Hypercalcemia (high calcium levels)*** - **Hypercalcemia** is the most commonly reported electrolyte abnormality with chronic lithium therapy, occurring in **10-15% of patients**. - Lithium can cause **hyperparathyroidism** by affecting parathyroid gland function, leading to increased PTH secretion and subsequent elevation of serum calcium levels [2]. - This effect can develop after **months to years** of lithium treatment and may persist even after lithium discontinuation. - Regular monitoring of serum calcium and PTH levels is recommended during long-term lithium therapy. *Hypernatremia (high sodium levels)* - **Hypernatremia** is not a direct or common electrolyte imbalance from lithium itself. - While lithium can cause **nephrogenic diabetes insipidus (NDI)** leading to polyuria and polydipsia, patients typically maintain normal sodium levels if they have adequate water access [1], [3]. - Hypernatremia may occur as a **secondary complication** if patients with lithium-induced NDI become dehydrated, but this is not the primary electrolyte abnormality. *Hyperkalemia (high potassium levels)* - **Hyperkalemia** is not typically associated with lithium treatment. - Lithium's effects on renal function do not consistently lead to significant alterations in potassium homeostasis. *Hypokalemia (low potassium levels)* - **Hypokalemia** is not a characteristic electrolyte imbalance with lithium therapy. - Lithium primarily affects water handling and calcium metabolism rather than potassium balance.

Q: Which of the following is a side effect of quetiapine?

Dry mouth. ***Dry mouth*** - **Quetiapine** is an atypical antipsychotic that commonly causes **anticholinergic side effects**, including **dry mouth (xerostomia)**. - This symptom results from the drug's antagonistic activity at **muscarinic acetylcholine receptors**. - Dry mouth is a **frequent and well-recognized side effect** occurring in a significant proportion of patients, making it the best answer among the options provided. *Sudden cardiac death* - Quetiapine can cause **QT interval prolongation**, particularly at higher doses or in susceptible individuals, which may increase the risk of **fatal cardiac arrhythmias**. - However, sudden cardiac death is a **rare but serious adverse event**, not a common side effect seen in routine clinical practice. - While this is a documented risk requiring monitoring, **dry mouth is far more frequently encountered** in patients taking quetiapine. *Dyspepsia* - **Dyspepsia (indigestion)** can occur with various medications, but it is not a particularly prominent or characteristic side effect of **quetiapine**. - The more notable side effects of quetiapine include **sedation, weight gain, metabolic effects, and anticholinergic symptoms** rather than gastrointestinal upset. *Hair loss* - **Hair loss (alopecia)** is not a recognized or documented side effect of **quetiapine**. - This is not typically associated with atypical antipsychotics and would not be expected with quetiapine therapy.

Q: What is the drug of choice (DOC) for a schizophrenic patient with poor oral absorption?

Fluphenazine. ***Fluphenazine*** - **Fluphenazine** is available as a **long-acting injectable** (LAI) formulation, specifically **fluphenazine decanoate**, making it an ideal choice for patients with **poor oral absorption** or adherence issues. - Its **depot injection** bypasses the need for oral intake, ensuring therapeutic drug levels are maintained over several weeks. *Clozapine* - **Clozapine** is an **oral antipsychotic** and requires consistent oral intake for efficacy. - It is often reserved for **treatment-resistant schizophrenia** and is not available in a long-acting injectable form suitable for poor oral absorption. *Sulpride* - **Sulpride** is primarily an **oral antipsychotic** and its administration relies on adequate oral absorption. - It is not available in a formulation that would circumvent issues of poor oral absorption. *Penfluridol* - **Penfluridol** is an **oral long-acting antipsychotic**, but it still requires oral administration. - While long-acting, its efficacy depends on the patient's ability to absorb the drug orally, which is compromised in this scenario.

Q: Which of the following conditions is NOT a contraindication for the use of Tricyclic Antidepressants (TCAs)?

Impaired renal function. ***Impaired renal function*** - While **Tricyclic Antidepressants (TCAs)** are metabolized in the liver and excreted by the kidneys, **impaired renal function** alone is generally not considered an absolute contraindication but necessitates **dose adjustments** and careful monitoring. - The primary concern with renal impairment is the **accumulation of active metabolites**, which can increase the risk of side effects, but it doesn't preclude their use entirely. *Narrow angle glaucoma* - TCAs have **anticholinergic properties** that can cause mydriasis (pupil dilation), which can precipitate an acute attack in individuals with **narrow-angle glaucoma**. - This is an important contraindication due to the risk of **irreversible vision loss**. *Prostate hypertrophy* - The **anticholinergic effects** of TCAs can worsen urinary retention in patients with **prostate hypertrophy** by relaxing the detrusor muscle and contracting the bladder sphincter. - This can lead to increased discomfort and potentially acute urinary retention. *A patient on MAO inhibitors* - Concomitant use of TCAs with **MAO inhibitors** is an absolute contraindication due to the risk of **hypertensive crisis** and **hyperpyrexia** from potentiation of noradrenergic effects. - This dangerous interaction can lead to severe and potentially fatal symptoms such as hyperthermia, severe hypertension, seizures, and cardiovascular collapse. A washout period of at least 2 weeks is required when switching between these medications.

Q: What is the primary use of Acamprosate in medical treatment?

Alcohol abstinence. ***Alcohol abstinence*** - **Acamprosate** is primarily used to maintain **abstinence from alcohol** in patients recovering from alcohol dependence. - It works by restoring the balance of **neurotransmitters** in the brain, particularly **GABA** and **glutamate**, which are often disrupted by chronic alcohol use. *Nicotine abstinence* - Medications for **nicotine abstinence** typically include **varenicline**, bupropion, or nicotine replacement therapies. - **Acamprosate** does not have a primary indication or established efficacy for smoking cessation. *Opioid abstinence* - **Opioid dependence** is commonly treated with medications such as **methadone**, **buprenorphine**, or naltrexone for maintenance and relapse prevention. - **Acamprosate** is not indicated for the management of opioid withdrawal or opioid use disorder. *Cocaine abstinence* - There are currently no FDA-approved medications specifically for treating **cocaine dependence**. - Treatment typically involves behavioral therapies, and **acamprosate** has not shown efficacy in this context.

Q: Which FDA approved drug is used for refractory schizophrenia?

Clozapine. ***Clozapine*** - **Clozapine** is an **atypical antipsychotic** uniquely approved for the treatment of **refractory schizophrenia**, where other antipsychotics have failed. - Its efficacy in treatment-resistant cases is attributed to its complex pharmacological profile, including antagonism of multiple **dopamine** and **serotonin receptors**. *Amoxapine* - **Amoxapine** is a **tetracyclic antidepressant** with some antipsychotic properties due to **dopamine receptor blockade**, but it is not a first-line or approved treatment for refractory schizophrenia. - It's primarily used for **major depressive disorder** and carries a risk of inducing **extrapyramidal symptoms**. *Haloperidol* - **Haloperidol** is a **first-generation (typical) antipsychotic** effective in treating acute psychotic symptoms but generally not used as the agent of choice for **refractory schizophrenia**. - Its primary mechanism involves potent **D2 dopamine receptor blockade**, which often leads to significant **extrapyramidal side effects**. *Penfluridol* - **Penfluridol** is a **long-acting, first-generation antipsychotic** that is used for maintenance treatment of schizophrenia, but it is not specifically indicated or uniquely effective for **refractory cases**. - It has a prolonged duration of action, making it suitable for patients requiring less frequent dosing to improve **medication adherence**.

Question 1

A patient with severe anxiety requires long-term management. Which class of antidepressants, known for its efficacy in treating anxiety disorders, should be considered?

Accepted Answer

Selective serotonin reuptake inhibitors (SSRIs)

Answer

Tricyclic antidepressants

Answer

Monoamine oxidase inhibitors

Answer

Atypical antipsychotics

Question 2

Which class of drugs is commonly used to treat anxiety by enhancing the effects of GABA?

Accepted Answer

Benzodiazepines

Answer

Selective serotonin reuptake inhibitors

Answer

Tricyclic antidepressants

Answer

Monoamine oxidase inhibitors

Question 3

A patient being treated with an antipsychotic drug develops tardive dyskinesia. Which class of antipsychotic drugs is most commonly associated with this condition?

Accepted Answer

Typical antipsychotics

Answer

Dopamine partial agonists

Answer

Anticholinergic drugs

Answer

Atypical antipsychotics

Question 4

A 30-year-old man presents with symptoms of depression. He is prescribed a selective serotonin reuptake inhibitor (SSRI). Which of the following drugs is he most likely taking?

Accepted Answer

Fluoxetine

Answer

Amitriptyline

Answer

Venlafaxine

Answer

Mirtazapine

Question 5

What is the most common electrolyte imbalance associated with lithium treatment?

Accepted Answer

Hypercalcemia (high calcium levels)

Answer

Hyperkalemia (high potassium levels)

Answer

Hypokalemia (low potassium levels)

Answer

Hypernatremia (high sodium levels)

Question 6

Which of the following is a side effect of quetiapine?

Accepted Answer

Dry mouth

Answer

Sudden cardiac death

Answer

Dyspepsia

Answer

Hair loss

Question 7

What is the drug of choice (DOC) for a schizophrenic patient with poor oral absorption?

Accepted Answer

Fluphenazine

Answer

Clozapine

Answer

Sulpride

Answer

Penfluridol

Question 8

Which of the following conditions is NOT a contraindication for the use of Tricyclic Antidepressants (TCAs)?

Accepted Answer

Impaired renal function

Answer

Narrow angle glaucoma

Answer

Prostate hypertrophy

Answer

A patient on MAO inhibitors

Question 9

What is the primary use of Acamprosate in medical treatment?

Accepted Answer

Alcohol abstinence

Answer

Nicotine abstinence

Answer

Opioid abstinence

Answer

Cocaine abstinence

Question 10

Which FDA approved drug is used for refractory schizophrenia?

Accepted Answer

Clozapine

Answer

Amoxapine

Answer

Haloperidol

Answer

Penfluridol

Drugs in Psychiatric Disorders — MCQs

Drugs in Psychiatric Disorders — MCQs

On this page

Practice by Chapter

Want unlimited practice?